Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 June;111(3) > Minerva Medica 2020 June;111(3):254-65

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Medica 2020 June;111(3):254-65

DOI: 10.23736/S0026-4806.20.06460-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis

Chunlei SUN, Jianxin XIA

Department of Dermatology, The Second Affiliated Hospital of JiLin University, Changchun, China



With the discovery of the IL-23 / Th17 axis, the treatment of psoriasis has entered a new era. The aim of this study was to explore the progress of biologics and janus kinases (JAK) inhibitors targeting IL-23/Th17 axis in the treatment of psoriasis. review of English-language article was performed. Search terms included IL-17, IL-23, biologics, monoclonal antibodies, neutralizing antibodies, JAK, inhibitors, Psoriasis Area Severity Index and psoriasis. Data were selected from two phase 2 clinical trials; and nine phase 3 randomized, double-blind clinical trials; and other clinical trials. This review analyzes skin lesion clearance and major adverse reactions of 9 mAbs including mirikizumab and bimekizumab. At the same time, the research progress and prospects of three non-IgG small molecule biologics are analyzed too. This paper also compares the efficacy and limitations of biologics targeting the IL-23/Th17 axis with non-biologics acting on the JAK-signal transducer and activator of transcription pathway. The IL-17A/F inhibitors and non-IgG small molecule biologics that are being studied will bring a revolutionary development to the treatment of psoriasis. Topical application of JAK inhibitors can not only achieve the purpose of treating psoriasis, but also reduce the amounts of systemic medication, and reduces side effects. Each drug has its own indication, and the effect of the drug can be better achieved by selecting the indication for the drug.


KEY WORDS: Interleukin-17; Interleukin-23; Antibodies, monoclonal; Psoriasis; Antibodies, neutralizing; Janus kinase

top of page